AJMC articleshttps://www.ajmc.com/newsAJMC articles© 2026 MJH Life Sciences™ and AJMC. All rights reserved.Wed, 24 Jun 2026 23:31:18 +00005en-us14447https://www.ajmc.com/newshttps://www.ajmc.com/logo.webphttps://www.ajmc.com/view/stigma-and-delayed-diagnosis-are-driving-up-obstructive-sleep-apnea-costshttps://www.ajmc.com/view/stigma-and-delayed-diagnosis-are-driving-up-obstructive-sleep-apnea-costs<![CDATA[Fear of CPAP deters patients with OSA from seeking care. Experts call for early diagnosis with oral devices and warn payers about the cost of delays.]]>Wed, 24 Jun 2026 20:50:44 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/fda-approves-palbociclib-for-hr-her2-breast-cancer-maintenancehttps://www.ajmc.com/view/fda-approves-palbociclib-for-hr-her2-breast-cancer-maintenance<![CDATA[FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.]]>Wed, 24 Jun 2026 19:29:51 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/patients-with-generalized-mg-saw-increased-burden-in-occupation-autonomyhttps://www.ajmc.com/view/patients-with-generalized-mg-saw-increased-burden-in-occupation-autonomy<![CDATA[Interviews with patients living with generalized myasthenia gravis (MG) in the US revealed areas of increased burden in these patients.]]>Wed, 24 Jun 2026 18:33:40 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/advancing-community-based-care-and-supporting-value-based-outcomeshttps://www.ajmc.com/view/advancing-community-based-care-and-supporting-value-based-outcomes<![CDATA[UPMC Health Plan’s Senior Health Expo served participants with free screenings, dental care, food assistance, and social resources to close care gaps.]]>Wed, 24 Jun 2026 16:45:27 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/zanubrutinib-tops-rivals-in-real-world-cll-survival-studyhttps://www.ajmc.com/view/zanubrutinib-tops-rivals-in-real-world-cll-survival-study<![CDATA[A Medicare claims analysis found zanubrutinib was associated with significantly longer treatment duration and overall survival vs acalabrutinib and ibrutinib.]]>Wed, 24 Jun 2026 16:06:38 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/cdc-officially-ends-hantavirus-response-as-outbreak-risk-recedeshttps://www.ajmc.com/view/cdc-officially-ends-hantavirus-response-as-outbreak-risk-recedes<![CDATA[The move follows the close of a 42-day quarantine for American cruise-ship passengers exposed to the rare Andes strain. ]]>Wed, 24 Jun 2026 15:29:56 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/respiratory-biologics-linked-to-reduced-asthma-exacerbations-across-patient-groupshttps://www.ajmc.com/view/respiratory-biologics-linked-to-reduced-asthma-exacerbations-across-patient-groups<![CDATA[Asthma biologics were associated with sustained reductions in exacerbations after 2015 across demographic and clinical subgroups in a large cohort study.]]>Wed, 24 Jun 2026 15:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/sglt2-inhibitors-tied-to-lower-platelet-activation-in-hfrefhttps://www.ajmc.com/view/sglt2-inhibitors-tied-to-lower-platelet-activation-in-hfref<![CDATA[A study found significant drops in mean platelet volume and rises in platelet count after 6 months of SGLT2 inhibitor therapy, independent of diuretic use.]]>Wed, 24 Jun 2026 13:03:43 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/examining-beladrd-bcma-targeting-and-contextualizing-early-mrd-datahttps://www.ajmc.com/view/examining-beladrd-bcma-targeting-and-contextualizing-early-mrd-data<![CDATA[BCMA ADC belantamab added to DRd shows striking MRD negativity in early myeloma trials, but eye toxicity and access shape frontline use.]]>Wed, 24 Jun 2026 12:05:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/long-term-management-in-retinal-vascular-diseaseshttps://www.ajmc.com/view/long-term-management-in-retinal-vascular-diseases<![CDATA[How longer-lasting therapies cut injection burden, boost adherence, and protect vision in AMD, DME, and RVO with new-generation treatments.]]>Wed, 24 Jun 2026 12:05:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/cepheus-at-6-years-counseling-transplant-ineligible-patients-and-managing-dvrd-in-frail-populationshttps://www.ajmc.com/view/cepheus-at-6-years-counseling-transplant-ineligible-patients-and-managing-dvrd-in-frail-populations<![CDATA[Cepheus data shows durable 6‑year control with DVRd, prompting new counseling and tailored dosing for frail, transplant‑ineligible myeloma patients.]]>Wed, 24 Jun 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/safety-and-durability-in-therapies-for-retinal-vascular-diseaseshttps://www.ajmc.com/view/safety-and-durability-in-therapies-for-retinal-vascular-diseases<![CDATA[New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.]]>Wed, 24 Jun 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/balancing-cost-utilization-and-risk-in-cll-treatment-adam-kittai-mdhttps://www.ajmc.com/view/balancing-cost-utilization-and-risk-in-cll-treatment-adam-kittai-md<![CDATA[From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL management still falls short.]]>Tue, 23 Jun 2026 21:30:34 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/attr-cm-incidence-prevalence-rose-sharply-in-the-ushttps://www.ajmc.com/view/attr-cm-incidence-prevalence-rose-sharply-in-the-us<![CDATA[Claims data show a 4- to 6-fold increase in ATTR-CM diagnoses, with a growing comorbidity burden before diagnosis.]]>Tue, 23 Jun 2026 20:31:50 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/rewriting-the-aml-treatment-playbook-tina-bhatnagar-dohttps://www.ajmc.com/view/rewriting-the-aml-treatment-playbook-tina-bhatnagar-do<![CDATA[Bhavana “Tina” Bhatnagar, DO, reflects on AML’s transformation from few treatment options to targeted therapies and efforts to increase access to them.]]>Tue, 23 Jun 2026 20:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/cv-health-in-pregnancy-linked-to-developmental-delay-in-childrenhttps://www.ajmc.com/view/cv-health-in-pregnancy-linked-to-developmental-delay-in-children<![CDATA[Children of mothers with poor cardiovascular health during pregnancy had nearly double the risk of developmental delay at age 4.]]>Tue, 23 Jun 2026 19:47:10 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/mixed-phase-3-results-for-ib6-targeting-adc-raise-questions-on-optimal-use-in-nsclchttps://www.ajmc.com/view/mixed-phase-3-results-for-ib6-targeting-adc-raise-questions-on-optimal-use-in-nsclc<![CDATA[The phase 3 SigVie-002 trial showed sigvotatug vedotin missed the OS end point, but the second-line subgroup showed a survival trend and manageable safety.]]>Tue, 23 Jun 2026 19:29:23 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/first-generic-of-priftin-approved-by-fda-for-tuberculosis-treatment-and-preventionhttps://www.ajmc.com/view/first-generic-of-priftin-approved-by-fda-for-tuberculosis-treatment-and-prevention<![CDATA[FDA approval of generic rifapentine introduces a new option for treating active tuberculosis and preventing progression of latent infection.]]>Tue, 23 Jun 2026 17:14:53 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/how-upstream-biologics-could-transform-crswnp-care-joseph-k-han-mdhttps://www.ajmc.com/view/how-upstream-biologics-could-transform-crswnp-care-joseph-k-han-md<![CDATA[Joseph K. Han, MD, discusses upstream biologics, verekitug, and the future of chronic rhinosinusitis with nasal polyps treatment.]]>Tue, 23 Jun 2026 17:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/familial-pulmonary-fibrosis-linked-to-faster-lung-function-decline-uip-patternhttps://www.ajmc.com/view/familial-pulmonary-fibrosis-linked-to-faster-lung-function-decline-uip-pattern<![CDATA[Patients with familial pulmonary fibrosis had faster FVC decline and were more likely to have a UIP pattern, supporting family history as a prognostic tool.]]>Tue, 23 Jun 2026 16:45:16 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/natera-s-moshkevich-discusses-tomr-approach-and-the-future-of-mrd-guided-carehttps://www.ajmc.com/view/natera-s-moshkevich-discusses-tomr-approach-and-the-future-of-mrd-guided-care<![CDATA[With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring adjuvant immunotherapy for patients with negative results for disease following surgery. ]]>Tue, 23 Jun 2026 16:34:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/structured-workup-allows-for-clearer-diagnoses-for-patients-with-chehttps://www.ajmc.com/view/structured-workup-allows-for-clearer-diagnoses-for-patients-with-che<![CDATA[Structured CHE diagnosis improves outcomes: a multicenter CRF clarifies causes for most patients with chronic hand eczema, addressing diagnosis challenges and guiding targeted care.]]>Tue, 23 Jun 2026 16:09:54 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/engagement-with-ai-cgm-platform-boosts-weight-loss-stephanie-kim-md-mphhttps://www.ajmc.com/view/engagement-with-ai-cgm-platform-boosts-weight-loss-stephanie-kim-md-mph<![CDATA[Adults with obesity using an AI-CGM platform lost weight nearly 3 times faster during engaged vs nonengaged periods (1.17% vs 0.44% per week).]]>Tue, 23 Jun 2026 16:01:55 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/ai-cgm-platform-engagement-linked-to-clinically-meaningful-weight-losshttps://www.ajmc.com/view/ai-cgm-platform-engagement-linked-to-clinically-meaningful-weight-loss<![CDATA[Real-world data show AI coaching plus CGM helps adults with obesity lose up to 7% in 6 months, with engagement driving faster weekly weight loss.]]>Tue, 23 Jun 2026 15:05:39 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/nurse-delivered-telehealth-falls-short-for-diabetes-in-fee-for-service-trialhttps://www.ajmc.com/view/nurse-delivered-telehealth-falls-short-for-diabetes-in-fee-for-service-trial<![CDATA[EXTEND trial data show nurse-delivered telehealth for type 2 diabetes missed its primary end point in fee-for-service care, raising questions about reimbursement.]]>Tue, 23 Jun 2026 14:42:22 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/switch-to-ocrelizumab-shows-safety-in-patients-with-relapsing-mshttps://www.ajmc.com/view/switch-to-ocrelizumab-shows-safety-in-patients-with-relapsing-ms<![CDATA[Patients with early relapsing multiple sclerosis (MS) were able to switch to ocrelizumab after suboptimal responses to other disease-modifying therapies.]]>Tue, 23 Jun 2026 14:19:19 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/topical-retinoids-for-acne-and-scarring-newer-formulations-expand-multimodal-optionshttps://www.ajmc.com/view/topical-retinoids-for-acne-and-scarring-newer-formulations-expand-multimodal-options<![CDATA[New formulations make topical retinoids for acne vulgaris and scarring more tolerable and effective, with promising data for trifarotene, tretinoin combinations, and retinols for acne.]]>Tue, 23 Jun 2026 13:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/the-right-fit-first-how-psychiatrists-approach-initial-treatment-and-patient-adherencehttps://www.ajmc.com/view/the-right-fit-first-how-psychiatrists-approach-initial-treatment-and-patient-adherence<![CDATA[Clinicians battle insurance formularies, using evidence, step-therapy strategy, and two‑week outcome tracking to secure affordable psychiatric meds.]]>Tue, 23 Jun 2026 12:05:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/formulary-frustrations-how-insurance-constraints-shape-psychiatric-treatment-decisionshttps://www.ajmc.com/view/formulary-frustrations-how-insurance-constraints-shape-psychiatric-treatment-decisions<![CDATA[Clinicians navigate insurance formularies, prior authorizations, and step therapy—using 14‑day check-ins and PHQ‑9 data to win better meds.]]>Tue, 23 Jun 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/social-factors-may-match-outpace-genetic-risk-in-disease-predictionhttps://www.ajmc.com/view/social-factors-may-match-outpace-genetic-risk-in-disease-prediction<![CDATA[The 2 risks operate independently so that social interventions can reduce disease risk regardless of a patient’s genetic profile.]]>Mon, 22 Jun 2026 20:44:06 GMTAJMCusAJMC Articles